March 15 Evening Shanghai and Shenzhen Listed Companies Major Events Announcement Latest Express

Shanghai and Shenzhen stock exchanges announced important company disclosures on the evening of March 15. Here is a summary of the key announcements.

Major Events

Daikin Heavy Industries: Recent UK government tariff adjustments do not affect the company’s related export product tariffs

Daikin Heavy Industries issued an abnormal stock trading fluctuation announcement, stating that the company’s stock price has deviated by more than 20% over the past two trading days. The recent UK government tariff adjustment policy does not impact tariffs on the company’s related export products. Recently, the UK announced the removal of 33 wind power component import tariffs starting April 1, 2026. The company’s wind tower and pipe pile products previously exported to the UK are not subject to tariffs, and this policy will not affect future tariff payments for the company’s products.

*ST Busen: Controlling shareholder plans to change control, stock suspension from tomorrow

*ST Busen announced that on March 13, it received notice from its controlling shareholder, Fang Weitongchuang, that it is planning to transfer control of the company, which may lead to a change in control. Currently, all parties are discussing specific plans and agreements. The company’s stock will be suspended from trading starting March 16, expected to last no more than two trading days.

Jingtou Development: Plans to transfer real estate development assets and liabilities to the controlling shareholder, likely constituting a major asset restructuring

Jingtou Development announced that it intends to transfer assets and liabilities related to its real estate development business to its controlling shareholder, Jingtou Company. The transfer will be paid in cash and will not involve issuing shares, nor will it affect the company’s ownership structure or result in a change of control. This is expected to constitute a major asset restructuring.

Zhaochi Co.: MicroLED applications in optical communication and other fields are currently in sample verification testing

Zhaochi Co. issued an abnormal stock trading fluctuation announcement, noting that the company’s stock price has deviated by more than 20% over three consecutive trading days. The company has observed high market interest in MicroLED concepts. The company’s main business remains unchanged, and MicroLED applications in optical communication and other fields are in the sample verification testing stage. This is unlikely to have a material impact on the company’s performance in the short term. The company’s operations are normal, with no significant changes in internal or external business environments.

Great Wisdom: Stock swap merger review suspended due to expired data

Great Wisdom announced that it and Xiangcai Co. are advancing a stock swap merger involving Xiangcai issuing A-shares to all A-share shareholders of Great Wisdom, along with raising funds through the issuance of A-shares. On March 14, 2026, the company received a notice from the Shanghai Stock Exchange that the valuation data submitted for the transaction has expired and needs updating. According to the rules for major asset restructuring review, the exchange has suspended review of the transaction. This suspension does not significantly affect the transaction, and the company’s operations are normal. The company and intermediaries are actively updating valuation and financial data, and will resubmit once completed.

Performance Highlights

Shantuo Co.: Net profit in 2025 increased by 9.86%, plans to pay 10 yuan per 1,000 shares

Shantuo Co. released its 2025 annual report, showing revenue of 14.62 billion yuan, up 2.82%; net profit attributable to shareholders of 1.211 billion yuan, up 9.86%; basic earnings per share of 0.81 yuan. The company plans to distribute a cash dividend of 1.0 yuan per 10 shares (tax included).

Lutianhua: Net profit in 2025 increased by 50.23%

Lutianhua disclosed its annual report, with revenue of 4.495 billion yuan, down 11.34%; net profit of 31.78 million yuan, up 50.23%; basic earnings per share of 0.02 yuan.

Beishidak: Net profit in 2025 decreased by 77.97%, plans to pay 0.3 yuan per 10 shares

Beishidak announced its annual report, with revenue of 838 million yuan, down 1.52%; net profit of 12.174 million yuan, down 77.97%; basic earnings per share of 0.04 yuan. The company plans to pay a cash dividend of 0.30 yuan per 10 shares (tax included).

*ST Jiawo: Loss of 427 million yuan in 2025

*ST Jiawo (300268) released its annual report on March 15, showing revenue of 1.657 billion yuan, down 51.51%; net loss of 427 million yuan, compared to a loss of 924 million yuan in the previous year.

Changes in holdings

Juchen Co.: Shareholder Beijing Luojia plans to reduce holdings by up to 2.61%

Juchen Co. announced that its shareholder, Beijing Luojia Tianhao Investment Center (Limited Partnership), plans to reduce its holdings by no more than 2.5412 million shares (1.61% of total shares) through block trades within three months after 15 trading days, and no more than 1.58 million shares (1%) through centralized bidding.

Share buyback

Qingniao Fire Protection: Plans to repurchase 2.5%-5% of shares

Qingniao Fire Protection announced plans to use its own funds and raised funds to repurchase shares via centralized bidding, at a price not exceeding 16.00 yuan per share. The repurchased shares will be no less than 2.5% of total shares (21,995,222 shares) and no more than 5% (43,990,443 shares). The repurchased shares will be used for employee stock ownership plans or equity incentives.

Major contracts awarded

Zhefu Holding: Wins bid for 412 million yuan hydropower generator and auxiliary equipment project

Zhefu Holding announced it received a bid-winning notice for a project involving hydropower generators and auxiliary equipment at the Changbo diversion hydropower station upstream of the Jinsha River, with a total bid amount of 412 million yuan, accounting for about 1.97% of the company’s 2024 revenue. With a 27-month delivery schedule, this will contribute approximately 0.73% of 2024 revenue per year, and is expected to increase sales revenue and net profit from 2027 to 2029.

Kede CNC: Co-establishes Excellence Innovation Center with Shanghai Flying Aircraft

Kede CNC (688305) announced on March 15 that it has signed a revised agreement with Shanghai Aircraft Manufacturing Co., Ltd. to detail the core research and development focus of the previously signed “Co-Construction Agreement.” The two parties will jointly establish an Excellence Innovation Center, focusing on processing techniques for typical aircraft parts, domestic equipment pilot verification, intelligent production line integration, and multi-domain collaborative “CNC workshop” development, based on Kede CNC’s自主高端五轴机床及其数控系统等国产关键核心部件。

Other News

Foton Motor: Adjusts directors and general manager

Foton Motor announced that on March 14 it received a letter from its controlling shareholder, Beijing Automotive Group Co., Ltd. (BAIC Group), recommending Lu Zhenghua as director and general manager. Wu Xibin will no longer serve as director or general manager.

Haisike: New drug HSK55879 approved for clinical trials

Haisike announced that its subsidiary, Shanghai Haisike Shengnuo Pharmaceutical Technology Co., Ltd., received the Drug Clinical Trial Approval Notice from the National Medical Products Administration. The review confirmed that the IND applications for HSK55879 for two indications, submitted in December 2025, meet registration requirements, and clinical trials for both indications are approved. HSK55879 is an independently developed, patent-protected new oral small-molecule agonist intended for metabolic system diseases.

China High-Tech: Subsidiary receives termination letter from Ping An Real Estate

China High-Tech announced that its wholly owned subsidiary, Beijing Gaoke Guorong Asset Management Co., Ltd., received a termination letter from its related party, Shenzhen Ping An Real Estate Investment Co., Ltd., on March 12, 2026. The asset management agreements signed in April 2024 and subsequent amendments are officially terminated from the date of receipt. Asset management work will be arranged separately by Ping An Real Estate. Since the company’s asset management business is still in development and contributes limited revenue, this termination will not significantly affect operations, finances, or ongoing viability.

Shengxiang Biotech: Plans to jointly invest with related parties to establish Huasi Wuwei

Shengxiang Biotech announced plans to jointly invest with its related party, Hunan Jinfurong Shengxiang Biotech Equity Investment Partnership, to establish Hunan Shengwei Huasi Biotech Co., Ltd., which will be the investment vehicle for subsequent acquisition of 100% equity of Huasi Wuwei Microbial Technology (Shenzhen) Co., Ltd. The company will contribute 65.438 million yuan in cash. After completion, Shengwei Huasi and Huasi Wuwei will be consolidated into the company’s financial statements. Huasi Wuwei specializes in R&D, production, and sales of in vitro diagnostic reagents and instruments based on its proprietary infrared fluorescence enhancement technology, for human and veterinary use.

Warner Pharmaceutical: Subsidiary passes FDA on-site inspection

Warner Pharmaceutical announced that its wholly owned subsidiary, Hunan Warner Big Pharma Chiral Drug Co., Ltd., underwent an FDA pre-approval inspection from November 10 to 14, 2025. The company received the FDA’s on-site inspection report, confirming that the production line for pantoprazole sodium raw material meets FDA requirements, which will positively impact future performance and enhance international competitiveness.

True Love Home: Clarifies no involvement in AI business, main business unchanged

True Love Home issued an abnormal stock fluctuation notice, stating that its stock price has deviated by more than 20% over two trading days. The company has verified rumors circulating online that it will change its main business or be taken over. The company’s main business remains home textile products, mainly blankets, with no involvement in AI. The core business remains unchanged. The controlling shareholder has no plans or arrangements to list assets via a shell company within the next 36 months.

Aidi Pharmaceutical: Dotravirine tablets approved for drug registration

Aidi Pharmaceutical (688488) announced on March 15 that it received the Drug Registration Certificate for Dotravirine tablets, approved by the NMPA on March 10. The approved indication is for use in combination with other antiretroviral drugs to treat HIV-infected adults and children aged 12 and above.

Farsun: No equity relationship with Jiangsu Farsun Optical Communication Technology and other companies

Farsun issued an abnormal stock fluctuation announcement, stating that its stock price increased by 22.62% over two days on March 12 and 13, and by 107.68% over 20 consecutive trading days since February 6, 2026. The stock price has deviated significantly from fundamentals, posing risks of irrational speculation. The company may request a trading halt for investigation if prices continue to rise. The company’s business does not involve “special optical fiber” or “fiber optics,” nor does it involve “restructuring” or “being taken over.” The mentioned subsidiaries, Jiangsu Farsun Optical Communication Technology and Jiangsu Farsun Optoelectronic Technology, are under the control of the company’s major shareholder and have no ownership or business relations with the listed company. As of this announcement, there are no plans to restructure these subsidiaries.